Identification of New MiRNA Biomarkers Associated with HER2-positive Breast Cancers

Overview

Journal Oncoscience

Specialty Oncology

Date 2015 Dec 24

PMID 26697527

Citations 12

Authors

Hossam Tashkandi

Nirav Shah

Yogin Patel

Hexin Chen

Affiliations

Soon will be listed here.

Abstract

Human epidermal growth factor receptor 2 (HER2) is overexpressed/amplified in ∼30% breast cancers which are associated with poor prognosis. microRNAs are small non-coding RNA which play an important role in many physiological conditions including cancer. Here we screened and identified many miRNAs which are dysregulated by HER2 overexpression. In line with our quantitative PCR analysis data, in silico analysis of microRNA expression profiles of 1302 breast tumors revealed that miR-146a-5p is up-regulated and miR-181d and miR-195-5p are down-regulated in HER2-positive tumors. Furthermore, the expression levels of these microRNAs can significantly predict patient survival and thus potentially serve as new prognostic markers for HER2-positive breast cancer.

Citing Articles

Involvement of FAM170B-AS1, hsa-miR-1202, and hsa-miR-146a-5p in breast cancer.

Abd ELhafeez A, Ghanem H, Swellam M, Taha A Cancer Biomark. 2024; 39(4):313-333.

PMID: 38250762 PMC: 11091646. DOI: 10.3233/CBM-230396.

Hsa-miR-221-3p promotes proliferation and migration in HER2-positive breast cancer cells by targeting LASS2 and MBD2.

Shao X, Zheng Y, Huang Y, Li G, Zou W, Shi L Histol Histopathol. 2022; 37(11):1099-1112.

PMID: 35734966 DOI: 10.14670/HH-18-483.

Breast Cancer Subtype-Specific miRNAs: Networks, Impacts, and the Potential for Intervention.

Arun R, Cahill H, Marcato P Biomedicines. 2022; 10(3).

PMID: 35327452 PMC: 8945552. DOI: 10.3390/biomedicines10030651.

Circulating and Intracellular miRNAs as Prognostic and Predictive Factors in HER2-Positive Early Breast Cancer Treated with Neoadjuvant Chemotherapy: A Review of the Literature.

Isca C, Piacentini F, Mastrolia I, Masciale V, Caggia F, Toss A Cancers (Basel). 2021; 13(19).

PMID: 34638377 PMC: 8508299. DOI: 10.3390/cancers13194894.

microRNA Expression Profile in Single Hormone Receptor-Positive Breast Cancers is Mainly Dependent on HER2 Status-A Pilot Study.

Kunc M, Popeda M, Niemira M, Szalkowska A, Bienkowski M, Peksa R Diagnostics (Basel). 2020; 10(9).

PMID: 32825530 PMC: 7555149. DOI: 10.3390/diagnostics10090617.

References

Lo P, Kanojia D, Liu X, Singh U, Berger F, Wang Q . CD49f and CD61 identify Her2/neu-induced mammary tumor-initiating cells that are potentially derived from luminal progenitors and maintained by the integrin-TGFβ signaling. Oncogene. 2011; 31(21):2614-26. PMC: 3260386. DOI: 10.1038/onc.2011.439. View

Bailey S, Westerling T, Brown M . Loss of estrogen-regulated microRNA expression increases HER2 signaling and is prognostic of poor outcome in luminal breast cancer. Cancer Res. 2014; 75(2):436-45. PMC: 4297564. DOI: 10.1158/0008-5472.CAN-14-1041. View

Taganov K, Boldin M, Chang K, Baltimore D . NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci U S A. 2006; 103(33):12481-6. PMC: 1567904. DOI: 10.1073/pnas.0605298103. View

Mattie M, Benz C, Bowers J, Sensinger K, Wong L, Scott G . Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol Cancer. 2006; 5:24. PMC: 1563474. DOI: 10.1186/1476-4598-5-24. View

Perou C . Molecular stratification of triple-negative breast cancers. Oncologist. 2011; 16 Suppl 1:61-70. DOI: 10.1634/theoncologist.2011-S1-61. View

Lee Y, Ahn C, Han J, Choi H, Kim J, Yim J . The nuclear RNase III Drosha initiates microRNA processing. Nature. 2003; 425(6956):415-9. DOI: 10.1038/nature01957. View

Lowery A, Miller N, Devaney A, McNeill R, Davoren P, Lemetre C . MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer. Breast Cancer Res. 2009; 11(3):R27. PMC: 2716495. DOI: 10.1186/bcr2257. View

Perou C, Sorlie T, Eisen M, van de Rijn M, Jeffrey S, Rees C . Molecular portraits of human breast tumours. Nature. 2000; 406(6797):747-52. DOI: 10.1038/35021093. View

Ouyang M, Li Y, Ye S, Ma J, Lu L, Lv W . MicroRNA profiling implies new markers of chemoresistance of triple-negative breast cancer. PLoS One. 2014; 9(5):e96228. PMC: 4008525. DOI: 10.1371/journal.pone.0096228. View

10.

Feldman A, Koch W, Force T . Developing strategies to link basic cardiovascular sciences with clinical drug development: another opportunity for translational sciences. Clin Pharmacol Ther. 2007; 81(6):887-92. DOI: 10.1038/sj.clpt.6100160. View

11.

Tanic M, Zajac M, Gomez-Lopez G, Benitez J, Martinez-Delgado B . Integration of BRCA1-mediated miRNA and mRNA profiles reveals microRNA regulation of TRAF2 and NFκB pathway. Breast Cancer Res Treat. 2011; 134(1):41-51. DOI: 10.1007/s10549-011-1905-4. View

12.

Chen G, Umelo I, Lv S, Teugels E, Fostier K, Kronenberger P . miR-146a inhibits cell growth, cell migration and induces apoptosis in non-small cell lung cancer cells. PLoS One. 2013; 8(3):e60317. PMC: 3608584. DOI: 10.1371/journal.pone.0060317. View

13.

Bhaumik D, Scott G, Schokrpur S, Patil C, Campisi J, Benz C . Expression of microRNA-146 suppresses NF-kappaB activity with reduction of metastatic potential in breast cancer cells. Oncogene. 2008; 27(42):5643-7. PMC: 2811234. DOI: 10.1038/onc.2008.171. View

14.

Rubin I, Yarden Y . The basic biology of HER2. Ann Oncol. 2001; 12 Suppl 1:S3-8. DOI: 10.1093/annonc/12.suppl_1.s3. View

15.

Dvinge H, Git A, Graf S, Salmon-Divon M, Curtis C, Sottoriva A . The shaping and functional consequences of the microRNA landscape in breast cancer. Nature. 2013; 497(7449):378-82. DOI: 10.1038/nature12108. View

16.

Murphy C, Modi S . HER2 breast cancer therapies: a review. Biologics. 2009; 3:289-301. PMC: 2726059. View

17.

Iorio M, Ferracin M, Liu C, Veronese A, Spizzo R, Sabbioni S . MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005; 65(16):7065-70. DOI: 10.1158/0008-5472.CAN-05-1783. View

18.

Luo Q, Wei C, Li X, Li J, Chen L, Huang Y . MicroRNA-195-5p is a potential diagnostic and therapeutic target for breast cancer. Oncol Rep. 2014; 31(3):1096-102. PMC: 3926672. DOI: 10.3892/or.2014.2971. View

19.

Shen J, Ambrosone C, Dicioccio R, Odunsi K, Lele S, Zhao H . A functional polymorphism in the miR-146a gene and age of familial breast/ovarian cancer diagnosis. Carcinogenesis. 2008; 29(10):1963-6. DOI: 10.1093/carcin/bgn172. View

20.

Bartel D . MicroRNAs: target recognition and regulatory functions. Cell. 2009; 136(2):215-33. PMC: 3794896. DOI: 10.1016/j.cell.2009.01.002. View